• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Atopic Dermatitis: What's Best Treatment Practice?

Video
Conference|Maui Derm NP+PA Summer

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, explains dives into what 2022 is bringing to the AD space.

Related Videos
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
Elizabeth Kiracofe, MD, an expert on atopic dermatitis
Related Content
Social Media’s Influence on Consumers, TrenibotulinumtoxinE, and More From the SEASON Aesthetic Conference

Social Media’s Influence on Consumers, TrenibotulinumtoxinE, and More From the SEASON Aesthetic Conference

Article
The Cutaneous Connection: A Reminder of Patient Impact

The Cutaneous Connection: A Reminder of Patient Impact

Podcast
Derm-Biome and TransBIOtech Awarded $450,000 ARD Grant Funding for Inflammatory Disease and Skin Aging Research

Derm-Biome and TransBIOtech Awarded $450,000 ARD Grant Funding for Inflammatory Disease and Skin Aging Research

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Article
New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab

New Eblasakimab Data Shows Promise for Patients With AD and Inadequate Response to Dupilumab

Article
© 2024 MJH Life Sciences

All rights reserved.